Gigantism and Acromegaly - Biotech, Pharma and Life Science Channel
PubMed Articles
Aryl hydrocarbon receptor-interacting protein (AIP) is associated with 15-20 % of familial isolated pituitary adenomas and 50-80 % of cases with AIP mutation exhibit a somatotropinoma. Herein we rep...
ACCURACY OF CT AND MRI FOR CONTOURING THE FELINE OPTIC APPARATUS FOR RADIATION THERAPY PLANNING.
Consistency and accuracy in normal tissue contouring in radiotherapy planning is important for comparison of dosimetry and toxicity data between studies. The purpose of this study was to determine whe...
Somatostatin is a natural inhibitor of growth hormone, and its analogues are clinically used for the therapy of acromegaly, gigantism, thyrotropinoma, and other carcinoid syndrome. However, natural so...
Evaluation of thyroid diseases and differentiated thyroid cancer in acromegalic patients.
Thyroid diseases are frequently seen in patients with acromegaly. The aim of this study is to evaluate thyroid diseases and thyroid cancer in acromegalic patients followed in a single institution. The...
Type 1 drug hypersensitivity following first dose of pegvisomant.
The growth hormone receptor antagonist, pegvisomant (Somavert(™) ), is a generally well-tolerated medical treatment for acromegaly. Initial reports documenting safety and efficacy of pegvisomant sug...
Optimization of the medical treatment for acromegaly.
Somatostatin analogues are the cornerstone in the first-line and adjuvant (postsurgical) therapy in patients with acromegaly. These drugs highly effectively decrease serum concentrations of growth hor...
Fusiform dilatation of the cavernous carotid artery in acromegalic patients.
BACKGROUND: Surgeons undertaking transsphenoidal surgery in patients with acromegaly confront multiple unique challenges secondary to the anatomic alterations caused by growth hormone-secreting tumors...
Cardiovascular complications are the most common causes of morbidity and mortality in acromegaly. However, there is little data regarding cardiac autonomic functions in these patients. Herein, we aime...
Pasireotide has a broader somatostatin receptor binding profile than other somatostatin analogues. A 16-week, Phase II trial showed that pasireotide may be an effective treatment for acromegaly. An ex...
News Articles
Ipsen reports mixed Ph III results with Somatuline Autogel in patients with acromegaly
French drugmaker Ipsen (Euronext: IPN) announced the results of an international Phase IIIb study, PRIMARYS, assessing an investigational use of Somatuline Autogel (lanreotide) 120mg as first line the...
Statistical Significance Not Met for the Primary Endpoint, but Tumor Volume Reduction Observed in a Majority of Acromegalic Patients Ipsen (Euronext: IPN; ADR: IPSEY) today an...
Chiasma names Price executive chairman
Fredric Price said he stepped down as chairman and CEO of Chiasma Inc. (Jerusalem, Israel) on April 1. Price said he will remain at the company as executive chairman, a newly created position. Chiasma...
NEW YORK, NY and LONDON -- (Marketwired) -- 04/30/13 -- Celsus Therapeutics (OTCQB: MRRBY), an emerging growth, development-stage biotech company, announced the addition of Pharma/Biotech industry ve...
Embryology of Early Jurassic dinosaur from China with evidence of preserved organic remains
Fossil dinosaur embryos are surprisingly rare, being almost entirely restricted to Upper Cretaceous strata that record the late stages of non-avian dinosaur evolution. Notable exceptions are the oldes...
Aspireo Reports Somatoprim Phase IIa Proof of Concept Results in Acromegaly
Somatoprim reduces human growth hormone secretion safely and effectively in acromegaly patients Tel Aviv, Israel, April 3, 2013 / B3C newswire / - Aspireo Pharmaceuticals Limited (“Aspireo̶...
Roche and Chiasma to develop peptide somastatin analogue for neuroendocrine tumour applications
Roche and Chiasma Inc have established an agreement to develop and commercialise Chiasma’s proprietary product Octreolin, initially for acromegaly and subsequently for endocrine tumours. Octreolin i...
Roche in partnership with Chiasma for up to $600 million
Roche, a big pharma company, is in partnership to develop and commercialize Chiasma’s proprietary product Octreolin, initially for acromegaly and subsequently for neuroendocrine tumors. Octreoli...
Roche, Chiasma to develop Octreolin for acromegaly, neuroendocrine tumors
Basel, Switzerland-based Roche and Chiasma, a privately held biopharmaceutical company, have entered into an agreement to develop and commercialize Chiasma's proprietary product Octreolin, initially f...
[Chiasma] partners acromegaly candidate {Octreolin} with [Roche]
Israeli biotech [Chiasma Inc.] has licensed [Roche] exclusive global rights to its lead orphan drug candidate, Phase III {Octreolin} (octreotide). The first indication for the peptide therapeutic will...
Events
None
Companies
None
Clinical Trials
Non Interventional Post Marketing Programme in Acromegaly
The purpose of this study, is to assess the safety and local tolerability of the long-term use of Somatuline Autogel when administered by patients or their partners ("Home Injection Group"...
The morbidity and the mortality in acromegalic patients closely correspond to growth hormone (GH) levels and therefore efficient long-term treatment is important. Neurosurgery is the firs...
Measurement of Outcome of Surgical Treatment in Patients With Acromegaly
OBJECTIVES: I. Compare growth hormone (GH) levels at baseline and after glucose suppression measured with both a polyclonal radioimmunoassay and a highly sensitive immunoradiometric assay...
OBJECTIVES: I. Determine whether release of endogenous growth hormone (GH)-releasing hormone is involved in GH responses to clonidine, pyridostigmine, levodopa, arginine, GH-releasing pep...
Cardiac and Skeletal Muscle Energy Metabolism in Abnormal Growth Hormone States
Growth hormone (GH) is important for growth in childhood, but also has important effects on a number of tissues throughout life. GH deficiency and GH excess (acromegaly, caused by a pituit...
Use of Somatostatin Analogue Therapy as Primary Medical Treatment of Acromegaly
This study is designed to investigate the use of the somatostatin analogue- Somatuline Autogel in the primary medical treatment of the condition Acromegaly. Primary Objective: To test the...
Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
To evaluate the long-term efficacy and safety of repeated injections of lanreotide Autogel given in doses titrated to effect in acromegalic patients previously treated or not with somatost...
Acromegaly is a rare, serious condition characterized by chronic hypersecretion of growth hormone (GH), generally caused by a GH-secreting pituitary adenoma. This study will assess the lon...
Canadian Pegvisomant Compassionate Study In Acromegalic Patients
The purposes of this study are: 1) to provide SOMAVERT for compassionate use to patients with acromegaly or who have completed clinical trials and were responsive, and 2) to evaluate the s...
Long Term Study With B2036-PEG
Primary objective: To investigate the efficacy and safety of Pegvisomant in Japanese patients with acromegaly.
Videos
The World's Tallest Man: Still Growing
At over 8 feet tall, Sultan Kosen of Turkey is the world's tallest man. We follow his journey around the world in search of a cure for his gigantism, the lif...
Medical and Biotech [MESH] Definitions
Growth Hormone-secreting Pituitary Adenoma
A pituitary tumor that secretes GROWTH HORMONE. In humans, excess HUMAN GROWTH HORMONE leads to ACROMEGALY.
Proteus Syndrome
Hamartoneoplastic malformation syndrome of uncertain etiology characterized by partial GIGANTISM of the hands and/or feet, asymmetry of the limbs, plantar hyperplasia, hemangiomas (HEMANGIOMA), lipomas (LIPOMA), lymphangiomas (LYMPHANGIOMA), epidermal NEVI, macrocephaly, cranial HYPEROSTOSIS, and long-bone overgrowth. Joseph Merrick, the so-called "elephant man", apparently suffered from Proteus syndrome and not NEUROFIBROMATOSIS, a disorder with similar characteristics.
Sleep Apnea, Obstructive
A disorder characterized by recurrent apneas during sleep despite persistent respiratory efforts. It is due to upper airway obstruction. The respiratory pauses may induce HYPERCAPNIA or HYPOXIA. Cardiac arrhythmias and elevation of systemic and pulmonary arterial pressures may occur. Frequent partial arousals occur throughout sleep, resulting in relative SLEEP DEPRIVATION and daytime tiredness. Associated conditions include OBESITY; ACROMEGALY; MYXEDEMA; micrognathia; MYOTONIC DYSTROPHY; adenotonsilar dystrophy; and NEUROMUSCULAR DISEASES. (From Adams et al., Principles of Neurology, 6th ed, p395)
Acromegaly
A condition caused by prolonged exposure to excessive HUMAN GROWTH HORMONE in adults. It is characterized by bony enlargement of the FACE; lower jaw (PROGNATHISM); hands; FEET; HEAD; and THORAX. The most common etiology is a GROWTH HORMONE-SECRETING PITUITARY ADENOMA. (From Joynt, Clinical Neurology, 1992, Ch36, pp79-80)
Adenoma, Acidophil
A benign tumor, usually found in the anterior lobe of the pituitary gland, whose cells stain with acid dyes. Such pituitary tumors may give rise to excessive secretion of growth hormone, resulting in gigantism or acromegaly. A specific type of acidophil adenoma may give rise to nonpuerperal galactorrhea. (Dorland, 27th ed)
